Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 10/20 | 0.66 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.49 |
| ▸ | PDE2A | O00408 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | DDO | Q99489 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7884503 | 0.83 | RXFP1 (0.47) | DAOPDE3BPDE3APDE2ARXFP1 | |
| SCHEMBL16310134 | 0.79 | DAO (0.64) | DAODDO | |
| SCHEMBL13194528 | 0.79 | RXFP1 (0.56) | DAOPDE3BPDE3APDE2ARXFP1 | |
| SCHEMBL29859972 | 0.79 | RXFP1 (0.56) | DAOPDE3BPDE3APDE2ARXFP1 | |
| SCHEMBL1853447 | 0.79 | DAO (0.64) | DAOPDE3BPDE3APDE2ARXFP1 | |
| SCHEMBL14692256 | 0.78 | PDE3B (0.47) | DAOPDE3BPDE3APDE2ALMNA | |
| SCHEMBL30361050 | 0.78 | PDE3B (0.47) | DAOPDE3BPDE3APDE2ALMNA | |
| SCHEMBL22972569 | 0.77 | DAO (0.66) | DAOPDE3BPDE3APDE2ARXFP1 | |
| SCHEMBL19779729 | 0.77 | DAO (0.69) | DAOPDE3BPDE3APDE2ARXFP1 | |
| SCHEMBL3064318 | 0.77 | DAO (0.60) | DAOLMNAPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| WO-2022092084-A1 | FUSED HETEROCYCLE DERIVATIVE AND HERBICIDE CONTAINING SAME AS ACTIVE INGREDIENT | クミアイ化学工業株式会社 | 2022-05-05 | — | — | WO | disclosed |
| WO-2012028106-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | DAO 2844/4885PDE3B 2674/4885PDE3A 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.